Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes adverse effects: general ‐ movement disorders ‐ requiring… compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in clinical response: mental state ‐ relapse ‐ medium term Relapse rate compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Clinical response: mental state ‐ general score ‐ skew Brief Psychiatric Rating Scale (BPRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Movement disorders number of participants receiving antiparkinson medication · patients with schizophrenia
It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with other antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Perazine showed no clear difference in acceptability of treatment Leaving the studies early due to any reason compared with other antipsychotics (low certainty).
1 finding from 1 review
Satisfaction with care ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state change over time (no better or deterioration) · patients with schizophrenia
Perazine showed no clear difference in global state change over time (no better or deterioration) compared with other antipsychotics (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Global state: not improved ‐ short‐term GAF · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE changes global state: Not improved (talk, behaviour and expression still… compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Service outcomes: Hospitalisation · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
ACUPUNCTURE may leads to lower adverse effects: Extrapyramidal symptoms (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Quality of life: No clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review